Skip to main content
Fig. 6 | Stem Cell Research & Therapy

Fig. 6

From: Long noncoding RNA MEG3 blocks telomerase activity in human liver cancer stem cells epigenetically

Fig. 6

MEG3 reduces the telomere length by affecting the binding of POT1, ExoI, TRF2, SNM1B, and CST/AAF to telomeric DNA in human liver cancer stem cells. A RIP with anti-POT1, anti-ExoI, anti-TRF2, anti-SNM1B, and anti-P53. RT-PCR was used to detect HULC. IgG RNA RIP was used as a negative control. B RNA immunoprecipitation (RIP) with anti-P53 and then HULC was detected by RT-PCR. IgG RNA immunoprecipitation was used as a negative control. C CHIP using anti-POT1, anti-ExoI, anti-TRF2, anti-SNM1B, and anti-CST/AAF. IgG chromatin immunoprecipitation was used as a negative control. D (a) Super-RNA-protein complex gel migration assay (Super-EMSA) using biotin-labeled telomere probes (Biotin-Telomere) and anti-TRF2 and anti-biotin. IgG super-EMSA as a negative control. D (b) Quantitative analysis of gray scales of positive bands. E DNA PCR amplification-Southern blotting using telomere-specific primers. The amount of β-actin DNA amplification is referred to as INPUT. F Quantitative DNA PCR amplification for length. G DNA PCR amplification-Southern blotting using telomere-specific primers. The amount of β-actin DNA amplification is referred to as INPUT. H Quantitative DNA PCR amplification for length. The values of each group are expressed as mean ± standard deviation (mean ± SEM, n = 3), **P < 0.01, *P < 0.05)

Back to article page